Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -32.54% is 59% above its 5-year average of -79.49%, near the high end of its 5-year range (-180.98%–-24.73%).
4.31% below its 12-month average of -31.20%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -28.42%.
NET PROFIT MARGIN
-32.54%
NET PROFIT MARGIN AVG TTM
-31.20%
NET PROFIT MARGIN AVG 3Y
-43.94%
NET PROFIT MARGIN AVG 5Y
-79.49%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-4.31%
CURRENT VS 3Y AVG
+25.95%
CURRENT VS 5Y AVG
+59.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-12415.38%
vs the sector median at left
PROCEPT BioRobotics Corporation
Market Cap
$996.65M
Net Profit Margin
-32.54%
TTM Avg
-31.20%
3Y Avg
-43.94%
5Y Avg
-79.49%
Market Cap
$998.69M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-57.69%
Market Cap
$992.14M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.01B
Net Profit Margin
-493.26%
TTM Avg
-198.62%
3Y Avg
-139.13%
5Y Avg
-250.17%
Market Cap
$982.46M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$981.66M
Net Profit Margin
19.87%
TTM Avg
-292.21%
3Y Avg
-499.51%
5Y Avg
-430.28%
Market Cap
$978.09M
Net Profit Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
Net Profit Margin
-5.43%
TTM Avg
-0.76%
3Y Avg
-19.17%
5Y Avg
-21.06%
Market Cap
$973.93M
Net Profit Margin
1.96%
TTM Avg
-6.61%
3Y Avg
-1.16%
5Y Avg
6.17%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporation (PRCT) | $996.65M | -32.54% | -31.20% | -43.94% | -79.49% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | 0.00% | 0.00% | 0.00% | -57.69% |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| Immatics N.V. (IMTX)vs › | $1.01B | -493.26% | -198.62% | -139.13% | -250.17% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | 0.00% | 0.00% | 0.00% | 0.00% |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 19.87% | -292.21% | -499.51% | -430.28% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | -5.43% | -0.76% | -19.17% | -21.06% |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 1.96% | -6.61% | -1.16% | 6.17% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | -321.81% | -893.93% | -810.32% | -689.93% |
Operating Margin
-33.9%
Net Profit Margin
-32.5%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -28.42% |
| 2026-03-31 | -38.06% |
| 2025-12-31 | -39.07% |
| 2025-09-30 | -25.70% |
| 2025-06-30 | -24.73% |
| 2025-03-31 | -35.77% |
| 2024-12-31 | -27.63% |
| 2024-09-30 | -35.93% |
| 2024-06-30 | -48.03% |
| 2024-03-31 | -58.28% |
| 2023-12-31 | -63.11% |
| 2023-09-30 | -70.14% |
| 2023-06-30 | -76.38% |
| 2023-03-31 | -116.72% |
| 2022-12-31 | -118.48% |
| 2022-09-30 | -111.13% |
| 2022-06-30 | -114.94% |
| 2022-03-31 | -121.05% |
| 2021-12-31 | -180.98% |
| 2021-09-30 | -162.70% |
| 2021-06-30 | -172.02% |
| 2021-03-31 | -178.28% |
| 2020-12-31 | -474.32% |
| 2020-09-30 | -569.91% |
| 2020-06-30 | -1077.10% |
| 2020-03-31 | -1077.10% |
